GenKyoTex S.A.

29 articles about GenKyoTex S.A.

• Calliditas announces acquisition of remaining Genkyotex minority shares

  10/7/2021

  Calliditas Therapeutics AB announced that the company now controls 100% of the share capital of Genkyotex SA, after the completion of a centralized squeeze out offer to all minority shareholders.

• Positive Phase 1 results in high-dose setanaxib trial

  1/18/2021

  Genkyotex SA, a subsidiary of Calliditas Therapeutics AB, announced positive Phase 1 data demonstrating a favorable safety and pharmacokinetic profile of high-dose setanaxib, Genkyotex's lead asset.

• Calliditas closes acquisition of a controlling interest in Genkyotex SA

  11/3/2020

  Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; NASDAQ - CALT) today announced the closing of the acquisition of 62.7% of Genkyotex SA ("Genkyotex") (Euronext Paris & Brussels: FR0013399474 - GKTX) in an off-market transaction. On August 13, 2020 , Calliditas announced that it had entered into an agreeme

• Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA

  8/13/2020

  Transaction adds late-stage orphan pipeline asset and platform in inflammation and fibrosis. Calliditas to acquire 62.7% of Genkyotex for €20.3M in cash at €2.80 per share in an off-market transaction.

• 

  Clinical Catch-Up: December 2-5

  12/9/2019

  It was, as usual, a pretty busy week in clinical trial news. Here’s a look.

• Genkyotex Meets Both Primary and Secondary Interim Efficacy Endpoints in Phase 2 Trial of GKT831 in Primary Biliary Cholangitis

  11/5/2018

  After only 6 weeks of treatment, gamma glutamyl transpeptidase (GGT) levels were reduced by 23% in the 400mg BID group (p<0.01)

• 

  European VC Firm Forbion’s Fourth Fund Raises $316 Million

  7/11/2018

  It’s been a big year so far for activity in the U.S. biopharma market—record IPOs and plenty of big acquisitions. But things may be heating up in Europe as well.

• Genkyotex Reports December 31, 2017 Cash Position and Provides Business Update

  1/31/2018

  The cash position includes the €2.4 million payment of the 2016 Research Tax Credit received on December 2017.

• GenKyoTex S.A. Provides Business Update For Q2 2017

  7/28/2017

• GenKyoTex S.A. Initiates Patient Enrollment Into Phase II Trial Of GKT831 In Primary Biliary Cholangitis

  6/29/2017

• GenKyoTex S.A. Announces FDA Approval Of IND For Phase II Trial Of GKT831 In Patients With Primary Biliary Cholangitis

  5/3/2017

• GenKyoTex S.A. Provides Business Update For Q1 2017

  4/27/2017

• GenKyoTex S.A. 's GKT137831 Granted Orphan Drug Designation In The US And EU For The Treatment Of Systemic Sclerosis

  11/11/2015

• GenKyoTex S.A. CEO Resigns

  9/29/2015

• GenKyoTex S.A. Announces Leadership Transition

  9/29/2015

• GenKyoTex S.A. Announces Top-Line Results Of Phase 2 Clinical Program

  9/9/2015

• GenKyoTex S.A. ’s NOX1&4 Inhibitor Strategy In Liver Fibrosis Supported By New Preclinical Results

  7/30/2015

• GenKyoTex S.A. Raises CHF 20 Million ($21 Million)

  1/7/2015

• GenKyoTex S.A. Completes Enrollment Into Phase 2 Trial Of NOX1&4 Inhibitor GKT137831 In Diabetic Nephropathy

  11/13/2014

• GenKyoTex S.A. Announces New Senior Management And Board Appointments

  5/19/2014